ARTICLE | Company News

Boehringer Ingelheim, Eli Lilly sales and marketing update

October 26, 2015 7:00 AM UTC

Boehringer launched Synjardy empagliflozin/metformin in the U.S. to treat adults with Type II diabetes. The drug is indicated as an adjunct to diet and exercise to improve glycemic control in patients who are not adequately controlled on a regimen containing empagliflozin or metformin or patients already being treated with empagliflozin and metformin. The wholesale acquisition cost (WAC) for Synjardy is $6.05 per 5 or 12.5 mg tablet. The maximum recommended dose is 12.5 mg Synjardy given twice daily. ...